儿科急性淋巴细胞白血病中甲索的人口药理动力学和共变性分析
Biao Yu1, Ying Wan1, Kangkang Mei1
1Department of Pharmacy, Anhui Provincial Children's Hospital, Hefei, Anhui Province, People's Republic of China.
Drug design, development and therapy
|September 24, 2025
概括
这项研究开发了一种对儿科急性淋巴细胞白血病患者中甲状腺素的人口药理动力学模型. 该模型优化了剂量,特别是在功能障碍患者中,改善了治疗结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿科瘤学 儿科瘤学
- 临床药房 临床药房
背景情况:
- 甲托雷克萨特 (MTX) 在治疗儿科急性淋巴细胞白血病 (ALL) 中至关重要.
- 优化MTX剂量对于有效性和最小化儿童中毒性至关重要.
- 了解儿科ALL的MTX药理动力学 (PK) 对个性化治疗至关重要.
研究的目的:
- 在患有急性淋巴细胞白血病 (ALL) 的儿科患者中开发和验证甲索特雷克萨特 (MTX) 的人口药理动力学 (PPK) 模型.
- 评估共变量对MTX处置的影响,并探索最佳剂量方案.
- 通过为儿科ALL患者提供预测模型来增强MTX治疗.
主要方法:
- 对214名接受高剂量甲索特雷克萨特 (HD-MTX) 的儿科ALL患者的回顾性分析.
- 使用非线性混合效应建模 (NONMEM 7.4) 开发PPK模型,使用1672次血度测量.
- 使用蒙特卡洛模拟来优化剂量方案并评估预测性能的性能.
主要成果:
- 一个由两部分组成的模型将年龄 (截止时间为1年) 确定为关键因素. 确定了清除值 (CL) 和分布量 (V) 的种群典型值.
- 估计的淋巴膜过率 (eGFR),体重和血液尿素 (BUN) 显著影响了MTX清除.
- 该模型显示了令人满意的预测性能 (启动成功93.6%,MPE -3.99%,MAPE 22.4%),优化的剂量改善了功能障碍的MTX水平.
结论:
- 经过验证的PPK模型准确地预测了小儿ALL患者的MTX暴露.
- 功能状态 (eGFR) 是调整MTX加重剂量的关键决定因素.
- 对于患有功能不全的患者来说,调整充填剂量和输液时间可以提高稳定状态度的遵守性,减少延迟排泄,为临床决策提供信息.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Analysis of Population Pharmacokinetic Data
682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Dosage Regimens: Partial Pharmacokinetic Parameters
154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154


